Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2004-06-21

AUTHORS

Susumu Nakata, Tatsushi Yoshida, Mano Horinaka, Takumi Shiraishi, Miki Wakada, Toshiyuki Sakai

ABSTRACT

Death receptor 5 (DR5) is a receptor for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). TRAIL is a promising candidate for cancer therapeutics due to its ability to induce apoptosis selectively in cancer cells. Here, we report that histone deacetylase inhibitors (HDACIs) such as trichostatin A (TSA), sodium butyrate, and suberoylanilide hydroxamic acid (SAHA) upregulated DR5 expression in various human malignant tumor cells. An RNase protection assay demonstrated that HDACIs induced DR5 mRNA markedly but not that of other death receptor family members in Jurkat cells. HDACIs increased DR5 mRNA and protein in a dose- and time-dependent manner. We also show TSA increased DR5 promoter activity using a luciferase promoter assay. Furthermore, we demonstrated that HDACIs strongly sensitized exogenous soluble recombinant human TRAIL-induced apoptosis synergistically in Jurkat and HL-60 cells that were tolerant to TRAIL alone. The combined use of HDACIs and TRAIL in suboptimal concentrations induced Bid cleavage and activation of caspase-8, -10, -3, and -9. Human recombinant DR5/Fc chimera protein, zVAD-fmk pancaspase inhibitor, and caspase-8 and -10 inhibitors efficiently reduced apoptosis induced by cotreatment with HDACIs and TRAIL. Furthermore, TSA did not significantly induce DR5 protein and HDACIs did not enhance TRAIL-induced apoptosis in normal human peripheral blood mononuclear cells. These results suggest that this combined treatment with HDACIs and TRAIL is a promising strategy for new cancer therapeutics. More... »

PAGES

6261-6271

References to SciGraph publications

  • 2003-03-18. Interferon-α sensitizes human hepatoma cells to TRAIL-induced apoptosis through DR5 upregulation and NF-κB inactivation in ONCOGENE
  • 2001-08-01. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity in NATURE MEDICINE
  • 1997-10. KILLER/DR5 is a DNA damage–inducible p53–regulated death receptor gene in NATURE GENETICS
  • 2000-11-23. Activation of the p21WAF1/CIP1 promoter independent of p53 by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through the Sp1 sites in ONCOGENE
  • 2003-01. Apo2L/TRAIL and its death and decoy receptors in CELL DEATH & DIFFERENTIATION
  • 2000-01. The language of covalent histone modifications in NATURE
  • 1999-04-08. Mechanisms of apoptosis induced by the synthetic retinoid CD437 in human non-small cell lung carcinoma cells in ONCOGENE
  • 2002-09-05. Apo2L/TRAIL differentially modulates the apoptotic effects of sulindac and a COX-2 selective non-steroidal anti-inflammatory agent in Bax-deficient cells in ONCOGENE
  • 2001-04-01. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions in NATURE MEDICINE
  • 1999-11-11. Induction of the TRAIL receptor KILLER/DR5 in p53-dependent apoptosis but not growth arrest in ONCOGENE
  • 2003-04-03. Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway in ONCOGENE
  • 2000-03-30. Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site in ONCOGENE
  • 2003-10-30. p53-independent induction of Gadd45 by histone deacetylase inhibitor: coordinate regulation by transcription factors Oct-1 and NF-Y in ONCOGENE
  • 2000-05. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand in NATURE MEDICINE
  • 2002-04-18. Endoplasmic reticulum calcium pool depletion-induced apoptosis is coupled with activation of the death receptor 5 pathway in ONCOGENE
  • 1999-02. Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivo in NATURE MEDICINE
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1038/sj.onc.1207830

    DOI

    http://dx.doi.org/10.1038/sj.onc.1207830

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1049638392

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/15208660


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Clinical Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Oncology and Carcinogenesis", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Apoptosis", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Apoptosis Regulatory Proteins", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "BH3 Interacting Domain Death Agonist Protein", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Blotting, Western", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Carrier Proteins", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Caspases", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Cell Line, Tumor", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Enzyme Activation", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Enzyme Inhibitors", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Histone Deacetylase Inhibitors", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Hydrolysis", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Membrane Glycoproteins", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Promoter Regions, Genetic", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Receptors, TNF-Related Apoptosis-Inducing Ligand", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Receptors, Tumor Necrosis Factor", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "TNF-Related Apoptosis-Inducing Ligand", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Tumor Cells, Cultured", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Tumor Necrosis Factor-alpha", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Up-Regulation", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Department of Molecular-Targeting Cancer Prevention, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kawaramcahi-Hirokoji, Kamigyo-ku, 602-8566, Kyoto, Japan", 
              "id": "http://www.grid.ac/institutes/grid.272458.e", 
              "name": [
                "Department of Molecular-Targeting Cancer Prevention, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kawaramcahi-Hirokoji, Kamigyo-ku, 602-8566, Kyoto, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Nakata", 
            "givenName": "Susumu", 
            "id": "sg:person.015054254665.16", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015054254665.16"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Molecular-Targeting Cancer Prevention, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kawaramcahi-Hirokoji, Kamigyo-ku, 602-8566, Kyoto, Japan", 
              "id": "http://www.grid.ac/institutes/grid.272458.e", 
              "name": [
                "Department of Molecular-Targeting Cancer Prevention, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kawaramcahi-Hirokoji, Kamigyo-ku, 602-8566, Kyoto, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Yoshida", 
            "givenName": "Tatsushi", 
            "id": "sg:person.01265513077.75", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01265513077.75"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Applied Biochemistry, Kyoto Prefectural University, 606-8522, Kyoto, Japan", 
              "id": "http://www.grid.ac/institutes/grid.258797.6", 
              "name": [
                "Department of Molecular-Targeting Cancer Prevention, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kawaramcahi-Hirokoji, Kamigyo-ku, 602-8566, Kyoto, Japan", 
                "Department of Applied Biochemistry, Kyoto Prefectural University, 606-8522, Kyoto, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Horinaka", 
            "givenName": "Mano", 
            "id": "sg:person.01217377677.48", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01217377677.48"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Urology, Kyoto Prefectural University of Medicine, 602-8566, Kyoto, Japan", 
              "id": "http://www.grid.ac/institutes/grid.272458.e", 
              "name": [
                "Department of Molecular-Targeting Cancer Prevention, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kawaramcahi-Hirokoji, Kamigyo-ku, 602-8566, Kyoto, Japan", 
                "Department of Urology, Kyoto Prefectural University of Medicine, 602-8566, Kyoto, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Shiraishi", 
            "givenName": "Takumi", 
            "id": "sg:person.01356657633.67", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01356657633.67"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Molecular-Targeting Cancer Prevention, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kawaramcahi-Hirokoji, Kamigyo-ku, 602-8566, Kyoto, Japan", 
              "id": "http://www.grid.ac/institutes/grid.272458.e", 
              "name": [
                "Department of Molecular-Targeting Cancer Prevention, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kawaramcahi-Hirokoji, Kamigyo-ku, 602-8566, Kyoto, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Wakada", 
            "givenName": "Miki", 
            "id": "sg:person.0664220600.60", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0664220600.60"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Molecular-Targeting Cancer Prevention, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kawaramcahi-Hirokoji, Kamigyo-ku, 602-8566, Kyoto, Japan", 
              "id": "http://www.grid.ac/institutes/grid.272458.e", 
              "name": [
                "Department of Molecular-Targeting Cancer Prevention, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kawaramcahi-Hirokoji, Kamigyo-ku, 602-8566, Kyoto, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Sakai", 
            "givenName": "Toshiyuki", 
            "id": "sg:person.011042136772.64", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011042136772.64"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1038/sj.onc.1203025", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1032194524", 
              "https://doi.org/10.1038/sj.onc.1203025"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.cdd.4401187", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1000537525", 
              "https://doi.org/10.1038/sj.cdd.4401187"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.onc.1203963", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1006747665", 
              "https://doi.org/10.1038/sj.onc.1203963"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.onc.1205345", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1015264205", 
              "https://doi.org/10.1038/sj.onc.1205345"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/47412", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1025852070", 
              "https://doi.org/10.1038/47412"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.onc.1202543", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1031105532", 
              "https://doi.org/10.1038/sj.onc.1202543"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.onc.1206290", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1047996205", 
              "https://doi.org/10.1038/sj.onc.1206290"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.onc.1207091", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1020888713", 
              "https://doi.org/10.1038/sj.onc.1207091"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.onc.1205897", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1028847663", 
              "https://doi.org/10.1038/sj.onc.1205897"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/75045", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1044338034", 
              "https://doi.org/10.1038/75045"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/86397", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1004368073", 
              "https://doi.org/10.1038/86397"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/ng1097-141", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1040087526", 
              "https://doi.org/10.1038/ng1097-141"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/91000", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1047281881", 
              "https://doi.org/10.1038/91000"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/5517", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1010598958", 
              "https://doi.org/10.1038/5517"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.onc.1203489", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1045600742", 
              "https://doi.org/10.1038/sj.onc.1203489"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.onc.1206139", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1023435255", 
              "https://doi.org/10.1038/sj.onc.1206139"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2004-06-21", 
        "datePublishedReg": "2004-06-21", 
        "description": "Death receptor 5 (DR5) is a receptor for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). TRAIL is a promising candidate for cancer therapeutics due to its ability to induce apoptosis selectively in cancer cells. Here, we report that histone deacetylase inhibitors (HDACIs) such as trichostatin A (TSA), sodium butyrate, and suberoylanilide hydroxamic acid (SAHA) upregulated DR5 expression in various human malignant tumor cells. An RNase protection assay demonstrated that HDACIs induced DR5 mRNA markedly but not that of other death receptor family members in Jurkat cells. HDACIs increased DR5 mRNA and protein in a dose- and time-dependent manner. We also show TSA increased DR5 promoter activity using a luciferase promoter assay. Furthermore, we demonstrated that HDACIs strongly sensitized exogenous soluble recombinant human TRAIL-induced apoptosis synergistically in Jurkat and HL-60 cells that were tolerant to TRAIL alone. The combined use of HDACIs and TRAIL in suboptimal concentrations induced Bid cleavage and activation of caspase-8, -10, -3, and -9. Human recombinant DR5/Fc chimera protein, zVAD-fmk pancaspase inhibitor, and caspase-8 and -10 inhibitors efficiently reduced apoptosis induced by cotreatment with HDACIs and TRAIL. Furthermore, TSA did not significantly induce DR5 protein and HDACIs did not enhance TRAIL-induced apoptosis in normal human peripheral blood mononuclear cells. These results suggest that this combined treatment with HDACIs and TRAIL is a promising strategy for new cancer therapeutics.", 
        "genre": "article", 
        "id": "sg:pub.10.1038/sj.onc.1207830", 
        "isAccessibleForFree": false, 
        "isPartOf": [
          {
            "id": "sg:journal.1097543", 
            "issn": [
              "0950-9232", 
              "1476-5594"
            ], 
            "name": "Oncogene", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "37", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "23"
          }
        ], 
        "keywords": [
          "tumor necrosis factor-related apoptosis-inducing ligand", 
          "histone deacetylase inhibitors", 
          "death receptor 5", 
          "trichostatin A", 
          "human malignant tumor cells", 
          "TRAIL-induced apoptosis", 
          "malignant tumor cells", 
          "caspase-8", 
          "death receptor family members", 
          "receptor 5", 
          "Human recombinant DR5/Fc chimera protein", 
          "deacetylase inhibitors", 
          "DR5 mRNA", 
          "normal human peripheral blood mononuclear cells", 
          "human peripheral blood mononuclear cells", 
          "luciferase promoter assays", 
          "peripheral blood mononuclear cells", 
          "tumor cells", 
          "DR5/Fc chimera protein", 
          "cancer therapeutics", 
          "blood mononuclear cells", 
          "DR5 promoter activity", 
          "receptor family members", 
          "necrosis factor-related apoptosis-inducing ligand", 
          "factor-related apoptosis-inducing ligand", 
          "new cancer therapeutics", 
          "HL-60 cells", 
          "Bid cleavage", 
          "apoptosis-inducing ligand", 
          "promoter assays", 
          "promoter activity", 
          "chimera protein", 
          "pancaspase inhibitor", 
          "DR5 protein", 
          "time-dependent manner", 
          "mononuclear cells", 
          "Jurkat cells", 
          "DR5 expression", 
          "suboptimal concentrations", 
          "apoptosis", 
          "sodium butyrate", 
          "protein", 
          "cancer cells", 
          "RNase protection", 
          "inhibitors", 
          "cells", 
          "family members", 
          "mRNA", 
          "therapeutics", 
          "promising strategy", 
          "combined use", 
          "dose", 
          "Jurkat", 
          "receptors", 
          "treatment", 
          "expression", 
          "cleavage", 
          "activation", 
          "assays", 
          "APO2", 
          "butyrate", 
          "members", 
          "ligands", 
          "activity", 
          "manner", 
          "protection", 
          "concentration", 
          "ability", 
          "use", 
          "candidates", 
          "strategies", 
          "promising candidate", 
          "results"
        ], 
        "name": "Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells", 
        "pagination": "6261-6271", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1049638392"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1038/sj.onc.1207830"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "15208660"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1038/sj.onc.1207830", 
          "https://app.dimensions.ai/details/publication/pub.1049638392"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-12-01T06:24", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/article/article_389.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1038/sj.onc.1207830"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/sj.onc.1207830'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/sj.onc.1207830'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/sj.onc.1207830'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/sj.onc.1207830'


     

    This table displays all metadata directly associated to this object as RDF triples.

    323 TRIPLES      21 PREDICATES      135 URIs      110 LITERALS      27 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1038/sj.onc.1207830 schema:about N004627a2c7cf4486b241d97a25cec5fb
    2 N012936cb3efc478ba802c9560502b4d5
    3 N03fe991751554615b1982fbcdc5d3f07
    4 N063e956303d14678aab52411dbaea2c8
    5 N40c92c8fd26f4e14bdfd41caf5544af8
    6 N497b6f6f835746da9063259002b3ba57
    7 N65f6f3a9939446c2995a811b156ff408
    8 N75d75a33822c45b885e8df63870f5e38
    9 N796903ac18c8469b9b4e19509877b1fb
    10 N89ab8e5d7cd740d68fb493b04e454fc2
    11 N8ab2eded544d456090e606868a7b5698
    12 N8baf81c177a444c69292f7a324aaf147
    13 N8c56884a9b504a60ac200c8a8a99b167
    14 Naaf565de4a214064b88fe24ad6042774
    15 Nb4e3f1f726fb4df1aecd74cfac58fd3c
    16 Nd7f163c0e3504d2aaf4d438909cd2bcf
    17 Nd82451d542634995a1be9700b2a0f899
    18 Ndcab12f2c401487a92c304de07c98489
    19 Nee935bf0960c4504b350fe4a9c0e15ce
    20 Nf15bf338293f42b98a6ac11def43b84a
    21 anzsrc-for:11
    22 anzsrc-for:1103
    23 anzsrc-for:1112
    24 schema:author N1980f50c37324a3e93e23e70136a3e68
    25 schema:citation sg:pub.10.1038/47412
    26 sg:pub.10.1038/5517
    27 sg:pub.10.1038/75045
    28 sg:pub.10.1038/86397
    29 sg:pub.10.1038/91000
    30 sg:pub.10.1038/ng1097-141
    31 sg:pub.10.1038/sj.cdd.4401187
    32 sg:pub.10.1038/sj.onc.1202543
    33 sg:pub.10.1038/sj.onc.1203025
    34 sg:pub.10.1038/sj.onc.1203489
    35 sg:pub.10.1038/sj.onc.1203963
    36 sg:pub.10.1038/sj.onc.1205345
    37 sg:pub.10.1038/sj.onc.1205897
    38 sg:pub.10.1038/sj.onc.1206139
    39 sg:pub.10.1038/sj.onc.1206290
    40 sg:pub.10.1038/sj.onc.1207091
    41 schema:datePublished 2004-06-21
    42 schema:datePublishedReg 2004-06-21
    43 schema:description Death receptor 5 (DR5) is a receptor for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). TRAIL is a promising candidate for cancer therapeutics due to its ability to induce apoptosis selectively in cancer cells. Here, we report that histone deacetylase inhibitors (HDACIs) such as trichostatin A (TSA), sodium butyrate, and suberoylanilide hydroxamic acid (SAHA) upregulated DR5 expression in various human malignant tumor cells. An RNase protection assay demonstrated that HDACIs induced DR5 mRNA markedly but not that of other death receptor family members in Jurkat cells. HDACIs increased DR5 mRNA and protein in a dose- and time-dependent manner. We also show TSA increased DR5 promoter activity using a luciferase promoter assay. Furthermore, we demonstrated that HDACIs strongly sensitized exogenous soluble recombinant human TRAIL-induced apoptosis synergistically in Jurkat and HL-60 cells that were tolerant to TRAIL alone. The combined use of HDACIs and TRAIL in suboptimal concentrations induced Bid cleavage and activation of caspase-8, -10, -3, and -9. Human recombinant DR5/Fc chimera protein, zVAD-fmk pancaspase inhibitor, and caspase-8 and -10 inhibitors efficiently reduced apoptosis induced by cotreatment with HDACIs and TRAIL. Furthermore, TSA did not significantly induce DR5 protein and HDACIs did not enhance TRAIL-induced apoptosis in normal human peripheral blood mononuclear cells. These results suggest that this combined treatment with HDACIs and TRAIL is a promising strategy for new cancer therapeutics.
    44 schema:genre article
    45 schema:isAccessibleForFree false
    46 schema:isPartOf N0f06804fefba4f12a6291319e0e3efeb
    47 N221bf2e9cf1848f694c5996ecc1ee1e8
    48 sg:journal.1097543
    49 schema:keywords APO2
    50 Bid cleavage
    51 DR5 expression
    52 DR5 mRNA
    53 DR5 promoter activity
    54 DR5 protein
    55 DR5/Fc chimera protein
    56 HL-60 cells
    57 Human recombinant DR5/Fc chimera protein
    58 Jurkat
    59 Jurkat cells
    60 RNase protection
    61 TRAIL-induced apoptosis
    62 ability
    63 activation
    64 activity
    65 apoptosis
    66 apoptosis-inducing ligand
    67 assays
    68 blood mononuclear cells
    69 butyrate
    70 cancer cells
    71 cancer therapeutics
    72 candidates
    73 caspase-8
    74 cells
    75 chimera protein
    76 cleavage
    77 combined use
    78 concentration
    79 deacetylase inhibitors
    80 death receptor 5
    81 death receptor family members
    82 dose
    83 expression
    84 factor-related apoptosis-inducing ligand
    85 family members
    86 histone deacetylase inhibitors
    87 human malignant tumor cells
    88 human peripheral blood mononuclear cells
    89 inhibitors
    90 ligands
    91 luciferase promoter assays
    92 mRNA
    93 malignant tumor cells
    94 manner
    95 members
    96 mononuclear cells
    97 necrosis factor-related apoptosis-inducing ligand
    98 new cancer therapeutics
    99 normal human peripheral blood mononuclear cells
    100 pancaspase inhibitor
    101 peripheral blood mononuclear cells
    102 promising candidate
    103 promising strategy
    104 promoter activity
    105 promoter assays
    106 protection
    107 protein
    108 receptor 5
    109 receptor family members
    110 receptors
    111 results
    112 sodium butyrate
    113 strategies
    114 suboptimal concentrations
    115 therapeutics
    116 time-dependent manner
    117 treatment
    118 trichostatin A
    119 tumor cells
    120 tumor necrosis factor-related apoptosis-inducing ligand
    121 use
    122 schema:name Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells
    123 schema:pagination 6261-6271
    124 schema:productId N5d56cbc788ce4f25aa0231f39eee6315
    125 N9c3d3ae85f7745bbac2bc1c509eab9e9
    126 Na9601b7318314c5391ef6285a0052aff
    127 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049638392
    128 https://doi.org/10.1038/sj.onc.1207830
    129 schema:sdDatePublished 2022-12-01T06:24
    130 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    131 schema:sdPublisher Na46747717e3145bcbc42b1e68c53ebd6
    132 schema:url https://doi.org/10.1038/sj.onc.1207830
    133 sgo:license sg:explorer/license/
    134 sgo:sdDataset articles
    135 rdf:type schema:ScholarlyArticle
    136 N004627a2c7cf4486b241d97a25cec5fb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    137 schema:name Tumor Cells, Cultured
    138 rdf:type schema:DefinedTerm
    139 N012936cb3efc478ba802c9560502b4d5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    140 schema:name Membrane Glycoproteins
    141 rdf:type schema:DefinedTerm
    142 N03fe991751554615b1982fbcdc5d3f07 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    143 schema:name Hydrolysis
    144 rdf:type schema:DefinedTerm
    145 N063e956303d14678aab52411dbaea2c8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    146 schema:name Blotting, Western
    147 rdf:type schema:DefinedTerm
    148 N0f06804fefba4f12a6291319e0e3efeb schema:volumeNumber 23
    149 rdf:type schema:PublicationVolume
    150 N1980f50c37324a3e93e23e70136a3e68 rdf:first sg:person.015054254665.16
    151 rdf:rest N5265f1aa39884df087b260632ab2c2fd
    152 N221bf2e9cf1848f694c5996ecc1ee1e8 schema:issueNumber 37
    153 rdf:type schema:PublicationIssue
    154 N40c92c8fd26f4e14bdfd41caf5544af8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    155 schema:name Enzyme Inhibitors
    156 rdf:type schema:DefinedTerm
    157 N497b6f6f835746da9063259002b3ba57 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    158 schema:name TNF-Related Apoptosis-Inducing Ligand
    159 rdf:type schema:DefinedTerm
    160 N5265f1aa39884df087b260632ab2c2fd rdf:first sg:person.01265513077.75
    161 rdf:rest Nb0482408166b461bbd5a8ad1af091a5c
    162 N5d56cbc788ce4f25aa0231f39eee6315 schema:name doi
    163 schema:value 10.1038/sj.onc.1207830
    164 rdf:type schema:PropertyValue
    165 N65f6f3a9939446c2995a811b156ff408 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    166 schema:name Humans
    167 rdf:type schema:DefinedTerm
    168 N67ad5550f2424a33bcaef91c64aaf415 rdf:first sg:person.011042136772.64
    169 rdf:rest rdf:nil
    170 N75d75a33822c45b885e8df63870f5e38 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    171 schema:name Enzyme Activation
    172 rdf:type schema:DefinedTerm
    173 N796903ac18c8469b9b4e19509877b1fb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    174 schema:name Up-Regulation
    175 rdf:type schema:DefinedTerm
    176 N89ab8e5d7cd740d68fb493b04e454fc2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    177 schema:name Promoter Regions, Genetic
    178 rdf:type schema:DefinedTerm
    179 N8ab2eded544d456090e606868a7b5698 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    180 schema:name Caspases
    181 rdf:type schema:DefinedTerm
    182 N8baf81c177a444c69292f7a324aaf147 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    183 schema:name Histone Deacetylase Inhibitors
    184 rdf:type schema:DefinedTerm
    185 N8c56884a9b504a60ac200c8a8a99b167 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    186 schema:name Tumor Necrosis Factor-alpha
    187 rdf:type schema:DefinedTerm
    188 N930304642a35405a8ed05f2b04f26f95 rdf:first sg:person.01356657633.67
    189 rdf:rest Nfa1f02abe38e4cdab96408bc8577a152
    190 N9c3d3ae85f7745bbac2bc1c509eab9e9 schema:name pubmed_id
    191 schema:value 15208660
    192 rdf:type schema:PropertyValue
    193 Na46747717e3145bcbc42b1e68c53ebd6 schema:name Springer Nature - SN SciGraph project
    194 rdf:type schema:Organization
    195 Na9601b7318314c5391ef6285a0052aff schema:name dimensions_id
    196 schema:value pub.1049638392
    197 rdf:type schema:PropertyValue
    198 Naaf565de4a214064b88fe24ad6042774 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    199 schema:name Cell Line, Tumor
    200 rdf:type schema:DefinedTerm
    201 Nb0482408166b461bbd5a8ad1af091a5c rdf:first sg:person.01217377677.48
    202 rdf:rest N930304642a35405a8ed05f2b04f26f95
    203 Nb4e3f1f726fb4df1aecd74cfac58fd3c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    204 schema:name Apoptosis
    205 rdf:type schema:DefinedTerm
    206 Nd7f163c0e3504d2aaf4d438909cd2bcf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    207 schema:name Receptors, TNF-Related Apoptosis-Inducing Ligand
    208 rdf:type schema:DefinedTerm
    209 Nd82451d542634995a1be9700b2a0f899 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    210 schema:name Apoptosis Regulatory Proteins
    211 rdf:type schema:DefinedTerm
    212 Ndcab12f2c401487a92c304de07c98489 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    213 schema:name Carrier Proteins
    214 rdf:type schema:DefinedTerm
    215 Nee935bf0960c4504b350fe4a9c0e15ce schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    216 schema:name Receptors, Tumor Necrosis Factor
    217 rdf:type schema:DefinedTerm
    218 Nf15bf338293f42b98a6ac11def43b84a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    219 schema:name BH3 Interacting Domain Death Agonist Protein
    220 rdf:type schema:DefinedTerm
    221 Nfa1f02abe38e4cdab96408bc8577a152 rdf:first sg:person.0664220600.60
    222 rdf:rest N67ad5550f2424a33bcaef91c64aaf415
    223 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    224 schema:name Medical and Health Sciences
    225 rdf:type schema:DefinedTerm
    226 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
    227 schema:name Clinical Sciences
    228 rdf:type schema:DefinedTerm
    229 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
    230 schema:name Oncology and Carcinogenesis
    231 rdf:type schema:DefinedTerm
    232 sg:journal.1097543 schema:issn 0950-9232
    233 1476-5594
    234 schema:name Oncogene
    235 schema:publisher Springer Nature
    236 rdf:type schema:Periodical
    237 sg:person.011042136772.64 schema:affiliation grid-institutes:grid.272458.e
    238 schema:familyName Sakai
    239 schema:givenName Toshiyuki
    240 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011042136772.64
    241 rdf:type schema:Person
    242 sg:person.01217377677.48 schema:affiliation grid-institutes:grid.258797.6
    243 schema:familyName Horinaka
    244 schema:givenName Mano
    245 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01217377677.48
    246 rdf:type schema:Person
    247 sg:person.01265513077.75 schema:affiliation grid-institutes:grid.272458.e
    248 schema:familyName Yoshida
    249 schema:givenName Tatsushi
    250 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01265513077.75
    251 rdf:type schema:Person
    252 sg:person.01356657633.67 schema:affiliation grid-institutes:grid.272458.e
    253 schema:familyName Shiraishi
    254 schema:givenName Takumi
    255 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01356657633.67
    256 rdf:type schema:Person
    257 sg:person.015054254665.16 schema:affiliation grid-institutes:grid.272458.e
    258 schema:familyName Nakata
    259 schema:givenName Susumu
    260 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015054254665.16
    261 rdf:type schema:Person
    262 sg:person.0664220600.60 schema:affiliation grid-institutes:grid.272458.e
    263 schema:familyName Wakada
    264 schema:givenName Miki
    265 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0664220600.60
    266 rdf:type schema:Person
    267 sg:pub.10.1038/47412 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025852070
    268 https://doi.org/10.1038/47412
    269 rdf:type schema:CreativeWork
    270 sg:pub.10.1038/5517 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010598958
    271 https://doi.org/10.1038/5517
    272 rdf:type schema:CreativeWork
    273 sg:pub.10.1038/75045 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044338034
    274 https://doi.org/10.1038/75045
    275 rdf:type schema:CreativeWork
    276 sg:pub.10.1038/86397 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004368073
    277 https://doi.org/10.1038/86397
    278 rdf:type schema:CreativeWork
    279 sg:pub.10.1038/91000 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047281881
    280 https://doi.org/10.1038/91000
    281 rdf:type schema:CreativeWork
    282 sg:pub.10.1038/ng1097-141 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040087526
    283 https://doi.org/10.1038/ng1097-141
    284 rdf:type schema:CreativeWork
    285 sg:pub.10.1038/sj.cdd.4401187 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000537525
    286 https://doi.org/10.1038/sj.cdd.4401187
    287 rdf:type schema:CreativeWork
    288 sg:pub.10.1038/sj.onc.1202543 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031105532
    289 https://doi.org/10.1038/sj.onc.1202543
    290 rdf:type schema:CreativeWork
    291 sg:pub.10.1038/sj.onc.1203025 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032194524
    292 https://doi.org/10.1038/sj.onc.1203025
    293 rdf:type schema:CreativeWork
    294 sg:pub.10.1038/sj.onc.1203489 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045600742
    295 https://doi.org/10.1038/sj.onc.1203489
    296 rdf:type schema:CreativeWork
    297 sg:pub.10.1038/sj.onc.1203963 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006747665
    298 https://doi.org/10.1038/sj.onc.1203963
    299 rdf:type schema:CreativeWork
    300 sg:pub.10.1038/sj.onc.1205345 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015264205
    301 https://doi.org/10.1038/sj.onc.1205345
    302 rdf:type schema:CreativeWork
    303 sg:pub.10.1038/sj.onc.1205897 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028847663
    304 https://doi.org/10.1038/sj.onc.1205897
    305 rdf:type schema:CreativeWork
    306 sg:pub.10.1038/sj.onc.1206139 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023435255
    307 https://doi.org/10.1038/sj.onc.1206139
    308 rdf:type schema:CreativeWork
    309 sg:pub.10.1038/sj.onc.1206290 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047996205
    310 https://doi.org/10.1038/sj.onc.1206290
    311 rdf:type schema:CreativeWork
    312 sg:pub.10.1038/sj.onc.1207091 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020888713
    313 https://doi.org/10.1038/sj.onc.1207091
    314 rdf:type schema:CreativeWork
    315 grid-institutes:grid.258797.6 schema:alternateName Department of Applied Biochemistry, Kyoto Prefectural University, 606-8522, Kyoto, Japan
    316 schema:name Department of Applied Biochemistry, Kyoto Prefectural University, 606-8522, Kyoto, Japan
    317 Department of Molecular-Targeting Cancer Prevention, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kawaramcahi-Hirokoji, Kamigyo-ku, 602-8566, Kyoto, Japan
    318 rdf:type schema:Organization
    319 grid-institutes:grid.272458.e schema:alternateName Department of Molecular-Targeting Cancer Prevention, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kawaramcahi-Hirokoji, Kamigyo-ku, 602-8566, Kyoto, Japan
    320 Department of Urology, Kyoto Prefectural University of Medicine, 602-8566, Kyoto, Japan
    321 schema:name Department of Molecular-Targeting Cancer Prevention, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kawaramcahi-Hirokoji, Kamigyo-ku, 602-8566, Kyoto, Japan
    322 Department of Urology, Kyoto Prefectural University of Medicine, 602-8566, Kyoto, Japan
    323 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...